申请人:Taisho Pharmaceutical Co., Ltd.
公开号:EP2708537A1
公开(公告)日:2014-03-19
The compound represented by formula (IA)
or a pharmaceutically acceptable salt thereof is based on orexin (OX) receptor antagonist activity, is useful in the treatment and prevention of illnesses including sleep disorder, depression, anxiety disorder, panic disorder, schizophrenia, drug dependency, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorders, pain, gastrointestinal disease, epilepsy, inflammation, immunological disease, endocrinological related disease, and hypertension.
式 (IA) 所代表的化合物
或其药学上可接受的盐是基于奥曲肽 (OX) 受体拮抗剂活性的,可用于治疗和预防疾病,包括睡眠障碍、抑郁症、焦虑症、恐慌症、精神分裂症、药物依赖、阿尔茨海默病、帕金森病、亨廷顿舞蹈症、饮食失调、疼痛、胃肠道疾病、癫痫、炎症、免疫疾病、内分泌相关疾病和高血压。